IL266524A - Methods for drug discovery using a stem cell derivative of Schwann cells - Google Patents

Methods for drug discovery using a stem cell derivative of Schwann cells

Info

Publication number
IL266524A
IL266524A IL266524A IL26652419A IL266524A IL 266524 A IL266524 A IL 266524A IL 266524 A IL266524 A IL 266524A IL 26652419 A IL26652419 A IL 26652419A IL 266524 A IL266524 A IL 266524A
Authority
IL
Israel
Prior art keywords
methods
stem cell
drug discovery
schwann cells
derived schwann
Prior art date
Application number
IL266524A
Other languages
English (en)
Hebrew (he)
Original Assignee
Univ Cornell
Memorial Sloan Kettering Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Cornell, Memorial Sloan Kettering Cancer Center filed Critical Univ Cornell
Publication of IL266524A publication Critical patent/IL266524A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0062—General methods for three-dimensional culture
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0622—Glial cells, e.g. astrocytes, oligodendrocytes; Schwann cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5038—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving detection of metabolites per se
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5058—Neurological cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5073—Stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/01—Modulators of cAMP or cGMP, e.g. non-hydrolysable analogs, phosphodiesterase inhibitors, cholera toxin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/113—Acidic fibroblast growth factor (aFGF, FGF-1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/117—Keratinocyte growth factors (KGF-1, i.e. FGF-7; KGF-2, i.e. FGF-12)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/119—Other fibroblast growth factors, e.g. FGF-4, FGF-8, FGF-10
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/15—Transforming growth factor beta (TGF-β)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/415—Wnt; Frizzeled
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999—Small molecules not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/02—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from embryonic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2513/00—3D culture

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
IL266524A 2016-11-14 2019-05-08 Methods for drug discovery using a stem cell derivative of Schwann cells IL266524A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662421816P 2016-11-14 2016-11-14
PCT/US2017/061549 WO2018090006A1 (en) 2016-11-14 2017-11-14 Methods for drug discovery using stem cell-derived schwann cells

Publications (1)

Publication Number Publication Date
IL266524A true IL266524A (en) 2019-07-31

Family

ID=62110088

Family Applications (2)

Application Number Title Priority Date Filing Date
IL266524A IL266524A (en) 2016-11-14 2019-05-08 Methods for drug discovery using a stem cell derivative of Schwann cells
IL266554A IL266554A (en) 2016-11-14 2019-05-12 Stem cells derived from Schwann cells

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL266554A IL266554A (en) 2016-11-14 2019-05-12 Stem cells derived from Schwann cells

Country Status (9)

Country Link
US (2) US20190264173A1 (enExample)
EP (2) EP3538110A4 (enExample)
JP (4) JP2019535265A (enExample)
KR (1) KR20190077095A (enExample)
CN (2) CN110691601A (enExample)
AU (2) AU2017357072A1 (enExample)
CA (2) CA3043223A1 (enExample)
IL (2) IL266524A (enExample)
WO (2) WO2018090006A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL272246B1 (en) 2017-07-28 2025-09-01 Applied Therapeutics Inc Derivatives of 2-(4-oxo/thioketone/azo-3-((substituted)benzo[d]thiazol-2-yl)methyl)- 3,4-dihydrothieno[3,4-d]pyridazin-1-yl)acetic acid for use as aldose reductase inhibitors in treating galactosemia or preventing complications associated with galactosemia
CN111655336A (zh) * 2017-11-17 2020-09-11 纽约州立大学研究基金会 使用x射线微束辐射治疗受损周围神经的方法
JP7702784B2 (ja) * 2017-12-04 2025-07-04 ザ アドミニストレイターズ オブ ザ テューレイン エデュケイショナル ファンド スフェロイドを用いた細胞システムならびにそれらの製造方法及び使用方法
US11845989B2 (en) 2019-01-23 2023-12-19 Regeneron Pharmaceuticals, Inc. Treatment of ophthalmic conditions with angiopoietin-like 7 (ANGPTL7) inhibitors
EP3914711A2 (en) 2019-01-23 2021-12-01 Regeneron Pharmaceuticals, Inc. Treatment of ophthalmic conditions with angiopoietin-like 7 (angptl7) inhibitors
MX2021013511A (es) 2019-05-07 2022-02-23 Univ Miami Tratamiento y deteccion de neuropatias heredadas y trastornos asociados.
CN110157660A (zh) * 2019-06-10 2019-08-23 西安飞如生物科技有限公司 诱导成纤维细胞分泌抗菌肽的诱导培养基和方法、成纤维细胞及应用
JPWO2021166984A1 (enExample) * 2020-02-20 2021-08-26
EP3929281A1 (en) 2020-06-24 2021-12-29 Fachhochschule Technikum Wien Cell construct comprising schwann cells or schwann cell-like cells and a biocompatible matrix
MX2023009987A (es) 2021-02-26 2023-09-06 Regeneron Pharma Tratamiento de la inflamacion con glucocorticoides e inhibidores de angiopoyetina tipo 7 (angptl7).
AU2022291933A1 (en) * 2021-06-18 2024-01-18 Memorial Hospital For Cancer And Allied Diseases Methods of generating sacral neural crest lineages and uses thereof
EP4573186A1 (en) * 2022-08-16 2025-06-25 The Regents Of The University Of California Cell compositions and methods of using the same
WO2025170529A1 (en) 2024-02-09 2025-08-14 Hedlund Eva A method for deriving a multipotent neuromesodermal progenitor cell and/or daughter lineages, and related compositions

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000023568A2 (en) * 1998-10-06 2000-04-27 Albert Einstein College Of Medicine Of Yeshiva University Methods and compositions for decreasing mitochondrial overproduction of reactive oxygen species in cells
CN101066472B (zh) * 2007-04-18 2010-05-19 中国人民解放军第二军医大学 组织工程化周围神经移植体及其制备方法
JP5751548B2 (ja) * 2009-08-07 2015-07-22 国立大学法人京都大学 イヌｉＰＳ細胞及びその製造方法
WO2011046189A1 (ja) * 2009-10-15 2011-04-21 国立大学法人京都大学 神経変性疾患のモデル細胞、その製造方法及びその用途
CN102191217A (zh) * 2010-03-12 2011-09-21 上海市第一人民医院 一种诱导脐带间充质干细胞分化为类神经细胞的方法
PL2577318T3 (pl) 2010-05-25 2019-12-31 Memorial Sloan-Kettering Cancer Center Sposób różnicowania ludzkich embrionalnych komórek macierzystych do nocyceptorów i ich zastosowania
EP2627770B1 (en) * 2010-10-15 2017-06-28 Cornell University Compositions and methods for treating endocrine, gastrointestinal or autoimmune disorders
DK2675893T3 (en) * 2011-02-18 2019-04-15 Scripps Research Inst Directed differentiation of oligodendrocyte precursor cells into a myelinating cell fate
EP2614829A1 (en) * 2012-01-11 2013-07-17 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Mammalian neural plate border stem cells capable of forming neural tube and neural crest cell lineages including central and peripheral neurons
CA2914520A1 (en) * 2013-07-23 2015-01-29 F. Hoffmann-La Roche Ag Small molecule based conversion of somatic cells into neural crest cells
EP3027942B1 (en) * 2013-07-30 2019-07-03 Waters Technologies Corporation Check valve having polymeric seat and poppet
GB201318126D0 (en) * 2013-10-14 2013-11-27 Univ Cardiff Neuronal Stem Cell Differentiation
EP3071685A4 (en) 2013-11-21 2017-07-05 Memorial Sloan Kettering Cancer Center Specification of functional cranial placode derivatives from human pluripotent stem cells
ES2875315T3 (es) * 2014-09-12 2021-11-10 Kyoto Prefectural Public Univ Corp Células de Schwann y método para prepararlas
US20180140637A1 (en) * 2015-05-19 2018-05-24 Maya Sieber-Blum Epidermal neural crest stem cells as a source of schwann cells
KR101903458B1 (ko) * 2017-01-20 2018-10-02 한국생명공학연구원 슈반 세포 전구체 (Schwann cell precursor) 및 이로부터 분화된 슈반 세포 (Schwann cell)의 제조 방법

Also Published As

Publication number Publication date
CN110249047A (zh) 2019-09-17
CA3043226A1 (en) 2018-05-17
JP2022090133A (ja) 2022-06-16
JP2022059056A (ja) 2022-04-12
EP3538115A4 (en) 2020-04-22
JP2019535263A (ja) 2019-12-12
CN110691601A (zh) 2020-01-14
AU2017357076A1 (en) 2019-05-30
JP2019535265A (ja) 2019-12-12
US20190331666A1 (en) 2019-10-31
US20190264173A1 (en) 2019-08-29
EP3538110A4 (en) 2020-04-22
AU2017357072A1 (en) 2019-05-30
CA3043223A1 (en) 2018-05-17
IL266554A (en) 2019-07-31
EP3538110A1 (en) 2019-09-18
WO2018090002A1 (en) 2018-05-17
WO2018090006A1 (en) 2018-05-17
KR20190077095A (ko) 2019-07-02
EP3538115A1 (en) 2019-09-18

Similar Documents

Publication Publication Date Title
IL266524A (en) Methods for drug discovery using a stem cell derivative of Schwann cells
EP3170897A4 (en) Method for inducing t cells for immunocytotherapy from pluripotent stem cells
EP3158056A4 (en) Single cell-derived organoids
EP3345990A4 (en) SYSTEM FOR THE PRODUCTION OF PLURIPOTENTAL STEM CELLS
EP3195922A4 (en) Porous membrane
EP3165507A4 (en) Porous graphene preparation method
EP3134095A4 (en) Improved methods for manufacturing adoptive cell therapies
EP3137141A4 (en) Vaporizer
EP3122444B8 (en) Process for making membranes
IL257678A (en) Methods of stem cell transplantation
IL266111A (en) Methods for inducing a t-cell response
EP3237195A4 (en) Methods for producing pressware
EP3202896A4 (en) Method for culturing pluripotent stem cells
EP3228437A4 (en) Device for producing hollow container
EP3138903A4 (en) Cells for producing human antibody
EP3196297A4 (en) Method for producing cardiomyocyte population from pluripotent stem cells
EP3128003A4 (en) Medium for stem cell use
EP3196924A4 (en) Method for manufacturing microscopic structural body
EP3238744A4 (en) Method for modifying t cell population
EP3192640A4 (en) Hollow container and method for manufacturing hollow container
EP3450547A4 (en) PROCESS FOR PRODUCING ACTIVATED STEM CELLS
EP3242937A4 (en) Methods for producing abienol
EP3154349A4 (en) Methods for producing borylated arenes
IL248805A0 (en) A method for growing mature stem cells from whole blood
EP3198064A4 (en) Methods for sample preparation